Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-09-02

Clinical Trial Update: A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial of galantamine for mild to moderate Alzheimer's disease was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Galantamine (galantamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2013-09-02